Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC
Kristie L. Kahl
Published: Tuesday, Sep 25, 2018
The addition of atezolizumab (Tecentriq) to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival (PFS) in patients with stage IV nonsquamous non–small cell lung cancer (NSCLC).
... to read the full story